SCHEMBL4669863

SCHEMBL4669863

N#Cc1cc(O)n(-c2c(Cl)cc(C(F)(F)F)cc2Cl)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRB3 P28472 20/20 0.51
GABRA2 P47869 15/20 0.51
GABRB2 P47870 15/20 0.51
GABRP O00591 11/20 0.51
GABRD O14764 11/20 0.51
GABRA1 P14867 11/20 0.51
GABRB1 P18505 11/20 0.51
GABRG2 P18507 11/20 0.51
GABRA5 P31644 11/20 0.51
GABRA3 P34903 11/20 0.51
GABRA4 P48169 11/20 0.51
GABRE P78334 11/20 0.51
GABRA6 Q16445 11/20 0.51
GABRG1 Q8N1C3 11/20 0.51
GABRG3 Q99928 11/20 0.51
GABRQ Q9UN88 11/20 0.51
NR1I2 O75469 1/20 0.49
LMNA P02545 1/20 0.49
CYP3A4 P08684 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL239495 0.84 GABRB3 (0.60) GABRB3GABRA2GABRB2GABRPGABRD
Ammonia Solution, Strong SCHEMBL8425567 0.82 GABRB3 (0.59) GABRB3GABRA2GABRB2GABRPGABRD
Sulfurous Acid SCHEMBL28641882 0.80 GABRA2 (0.57) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL6708737 0.79 GABRB3 (0.46) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL20577971 0.79 BACE1 (0.51) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL28073555 0.78 GABRB3 (0.46) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL7713408 0.78 BACE1 (0.50) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL28641880 0.77 GABRA2 (0.54) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL14615157 0.76 GABRB3 (0.55) GABRB3GABRA2GABRB2GABRPGABRD
SCHEMBL2835184 0.76 GABRA2 (0.52) GABRB3GABRA2GABRB2GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237873-B1 CONTROL OF ARTHROPODS IN ANIMALS MERIAL LTD (US) 2013-04-03 EP disclosed
US-7468381-B2 Control of arthropods in animals MERIAL, INC. 2008-12-23 US disclosed
US-20070078127-A1 Control of arthropods in animals AVENTIS CROPSCIENCE S.A. (FR) 2007-04-05 US disclosed
US-6992099-B2 Control of arthropods in animals AVENTIS CROPSCIENCE S.A. (FR) 2006-01-31 US disclosed
US-20060020013-A1 Control of arthropods in animals AVENTIS CROPSCIENCE S.A. (FR) 2006-01-26 US disclosed
US-20030176466-A1 Control of arthropods in animals AVENTIS CROPSCIENCE S.A. (FR) 2003-09-18 US disclosed
US-6569886-B2 Control of arthropods in animals AVENTIS CROPSCIENCE S.A. (FR) 2003-05-27 US disclosed
EP-1237873-A2 CONTROL OF ARTHROPODS IN ANIMALS Bayer CropScience S.A. (FR) 2002-09-11 EP disclosed
US-20020111352-A1 Control of arthropods in animals MERIAL, INC. 2002-08-15 US disclosed
WO-2001040195-A2 CONTROL OF ARTHROPODS IN ANIMALS AVENTIS CROPSCIENCE S.A. (FR) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020111352-A1 Control of arthropods in animals CTRL, CYP3A43, PON1 GABRB3 1089/4885GABRA2 1597/4885GABRB2 1438/4885
US-20030176466-A1 Control of arthropods in animals CTRL, CYP3A43, PON1 GABRB3 1089/4885GABRA2 1597/4885GABRB2 1438/4885
US-20070078127-A1 Control of arthropods in animals CTRL, CYP3A43, PON1 GABRB3 1089/4885GABRA2 1597/4885GABRB2 1438/4885
US-20060020013-A1 Control of arthropods in animals CTRL, CYP3A43, PON1 GABRB3 1089/4885GABRA2 1597/4885GABRB2 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.